CNSP News and Press, CNS Pharmaceuticals Inc. From 11/07/22

CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma ( ...

Over the last 30 years, the five-year survival rate of patients with brain cancer in Australia hasn’t changed, remaining at about 22%. Now, researchers are planning to launch a clinical trial platform that will revolutionize studies on new treatments for brain cancer and help delive...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment o...

CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM PR Newswire Enrollment progressing toward interim analysis, planned when 30-50% of subjects reach 6 months i...

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). &...

Scientists have designed a new strategy to noninvasively track macrophages in tumors in the breast and brain. Macrophages are immune cells that play a crucial role in the immune system, carrying out a number of functions, including clearing out dead cells and digesting microorganisms. Thes...

Last week, a musician had his brain tumor removed while fully conscious during a nine-hour surgery that took place in Italy. During the operation, which was carried out at the Paideia International Hospital in Rome, the 35-year old musician played his saxophone. This helped the surgeon map...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2...

A new study has discovered a crucial new piece of information for the treatment and prevention of brain tumors. The study was led by Mount Sinai Hospital’s Lunenfeld-Tannenbaum Research Institute, in collaboration with the Mayo Clinic Center for Individualized Medicine and the May...